Subunit respiratory syncytial virus vaccine preparation
US6020182A · kind A · utility
4Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 1996 |
| Grant date | Feb 1, 2000 |
| Priority date | — |
| Expiry date | Jul 12, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18551
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or other ion-exchange matrix column and eluting the protein using mild salt treatment. The F, G and M proteins, formulated as immunogenic compositions, are safe and highly immunogenic and protect relevant animal models against respiratory syncytial virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.